Products Categories
CAS No.: | 129618-40-2 |
---|---|
Name: | Nevirapine |
Article Data: | 17 |
Molecular Structure: | |
Formula: | C15H14N4O |
Molecular Weight: | 266.302 |
Synonyms: | 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-one;Viramune;BIRG 0587;BI-RG-587;BI-RG-587;6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,11-cyclopropyl-5,11-dihydro-4-methyl-;99% Nevirapine;Nevirapine [USAN:INN];BI-RG 587;BIRG 587;BIRG 0587;Viramune (TN);NVP;Nevirapine (JP14/USAN);11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido;Viramune (Nevirapine); |
EINECS: | 603-345-0 |
Density: | 1.351 g/cm3 |
Melting Point: | 247 °C |
Boiling Point: | 415.4 °C at 760 mmHg |
Flash Point: | 205 °C |
Solubility: | 0.1g/L(temperature not stated) |
Appearance: | white or off-white crystalline powder |
Hazard Symbols: | Xi |
Risk Codes: | 36/37/38 |
Safety: | 26-36-37/39 |
PSA: | 63.57000 |
LogP: | 2.47830 |
N-(2-chloro-4-methyl-3-pyridinyl)-2-(cyclopropylamino)-3-pyridinecarboxamide
Nevirapine
Conditions | Yield |
---|---|
With diethylene glycol dimethyl ether; sodium hydride at 100 - 125℃; for 2.5h; Inert atmosphere; | 96% |
Stage #1: N-(2-chloro-4-methyl-3-pyridinyl)-2-(cyclopropylamino)-3-pyridinecarboxamide With potassium tert-butylate In diethylene glycol dimethyl ether at 100 - 110℃; for 1.5h; Stage #2: With acetic acid In diethylene glycol dimethyl ether at 5 - 10℃; pH=6.0 - 7.0; Product distribution / selectivity; | 83.39% |
Stage #1: N-(2-chloro-4-methyl-3-pyridinyl)-2-(cyclopropylamino)-3-pyridinecarboxamide With potassium tert-butylate In toluene at 100 - 110℃; for 3 - 3.5h; Stage #2: With sulfuric acid In water; toluene at 5 - 10℃; pH=1 - 7.0; Product distribution / selectivity; | 79.96% |
3-Amino-2-chloro-4-methylpyridine
Nevirapine
Conditions | Yield |
---|---|
With sodium hydride In diethylene glycol dimethyl ether at 65 - 165℃; Flow reactor; Green chemistry; | 96% |
Multi-step reaction with 2 steps 1.1: sodium hydride / 3.5 h / 30 - 60 °C / Inert atmosphere 1.2: 2 h / 55 - 65 °C / Inert atmosphere 2.1: sodium hydride; diethylene glycol dimethyl ether / 2.5 h / 100 - 125 °C / Inert atmosphere View Scheme | |
Multi-step reaction with 2 steps 1.1: sodium hydride / diethylene glycol dimethyl ether / 0.5 h / 20 °C 1.2: 2 h / 60 °C 2.1: sodium hydride / diethylene glycol dimethyl ether / 4 h / 105 - 117 °C / Green chemistry View Scheme |
2-(Cyclopropylamino)-N-(2-methoxy-4-methyl-3-pyridinyl)-3-pyridinecarboxamide
Nevirapine
Conditions | Yield |
---|---|
With pyridine; sodium hexamethyldisilazane at 90℃; for 6h; | 91% |
2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridinecarboxamide
Cyclopropylamine
Nevirapine
Conditions | Yield |
---|---|
Stage #1: 2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridinecarboxamide; Cyclopropylamine With triethylamine In toluene at 130℃; for 10h; Autoclave; Stage #2: With sodium amide In diethylene glycol dimethyl ether at 15 - 110℃; for 2h; Temperature; Time; Reagent/catalyst; Autoclave; | 86% |
Stage #1: 2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridinecarboxamide; Cyclopropylamine With calcium oxide In diethylene glycol dimethyl ether at 135 - 145℃; Stage #2: With sodium hydride at 140℃; for 0.5 - 1h; Stage #3: With water; acetic acid; ethyl acetate at 0 - 10℃; for 1 - 2h; |
2-chloro-11-cyclopropyl-6H-dipyrido<3,2-b:2',3'-e><1,4>diazepine-6-one
Nevirapine
Conditions | Yield |
---|---|
With hydrogen; palladium on activated charcoal In diethylene glycol dimethyl ether at 100℃; under 2585.7 Torr; for 12h; Yield given; |
2-Chloronicotinoyl chloride
Nevirapine
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1: 87 percent / CH2Cl2 / 1.) -78 deg C, 1 h, 2.) RT, 23 h 2: 94 percent / 4 h / 140 °C 3: 67 percent / 80percent NaH / bis-(2-methoxy-ethyl) ether / 1.5 h / 185 °C View Scheme | |
Multi-step reaction with 3 steps 1: 65.5 percent / pyridine / cyclohexane; dioxane / 48 h / Ambient temperature 2: 83 percent / xylene / 18 h / 110 °C 3: 67 percent / NaH / various solvent(s) / 1.5 h / Heating View Scheme | |
Multi-step reaction with 3 steps 1: pyridine / acetonitrile / 20 - 45 °C 2: calcium oxide / xylene / 140 °C 3: sodium hydrogen sulfate; copper(l) iodide; sulfuric acid; potassium tert-butylate / diethylene glycol dimethyl ether / 115 °C View Scheme |
2-chloronicotinic acid
Nevirapine
Conditions | Yield |
---|---|
Multi-step reaction with 4 steps 1: 99 percent / thionyl chloride / 1 h / Heating 2: 87 percent / CH2Cl2 / 1.) -78 deg C, 1 h, 2.) RT, 23 h 3: 94 percent / 4 h / 140 °C 4: 67 percent / 80percent NaH / bis-(2-methoxy-ethyl) ether / 1.5 h / 185 °C View Scheme | |
Multi-step reaction with 4 steps 1: potassium carbonate / N,N-dimethyl-formamide / 5 h / 60 - 65 °C 2: 5 h / 60 - 65 °C 3: 5%-palladium/activated carbon; hydrogen / ethanol; toluene / 6 h / 30 - 35 °C / 1500.15 - 2250.23 Torr / Autoclave 4: benzenesulfonic acid / 6 h / 90 - 95 °C View Scheme |
2-chloro-3-nitro-4-methylpyridine
Nevirapine
Conditions | Yield |
---|---|
Multi-step reaction with 4 steps 1: 98 percent / SnCl2 * 2 H2O, conc. HCl / diethyl ether / 0.33 h / Ambient temperature 2: 87 percent / CH2Cl2 / 1.) -78 deg C, 1 h, 2.) RT, 23 h 3: 94 percent / 4 h / 140 °C 4: 67 percent / 80percent NaH / bis-(2-methoxy-ethyl) ether / 1.5 h / 185 °C View Scheme | |
Multi-step reaction with 4 steps 1: 75 percent / H2 / 5percent Rh/C / ethanol / 3 h / 2585.7 Torr 2: 65.5 percent / pyridine / cyclohexane; dioxane / 48 h / Ambient temperature 3: 83 percent / xylene / 18 h / 110 °C 4: 67 percent / NaH / various solvent(s) / 1.5 h / Heating View Scheme | |
Multi-step reaction with 3 steps 1: 5 h / 60 - 65 °C 2: 5%-palladium/activated carbon; hydrogen / ethanol; toluene / 6 h / 30 - 35 °C / 1500.15 - 2250.23 Torr / Autoclave 3: benzenesulfonic acid / 6 h / 90 - 95 °C View Scheme |
3-Amino-2-chloro-4-methylpyridine
Nevirapine
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1: 87 percent / CH2Cl2 / 1.) -78 deg C, 1 h, 2.) RT, 23 h 2: 94 percent / 4 h / 140 °C 3: 67 percent / 80percent NaH / bis-(2-methoxy-ethyl) ether / 1.5 h / 185 °C View Scheme | |
Multi-step reaction with 3 steps 1: 65.5 percent / pyridine / cyclohexane; dioxane / 48 h / Ambient temperature 2: 83 percent / xylene / 18 h / 110 °C 3: 67 percent / NaH / various solvent(s) / 1.5 h / Heating View Scheme | |
Multi-step reaction with 3 steps 1: pyridine / acetonitrile / 20 - 45 °C 2: calcium oxide / xylene / 140 °C 3: sodium hydrogen sulfate; copper(l) iodide; sulfuric acid; potassium tert-butylate / diethylene glycol dimethyl ether / 115 °C View Scheme |
2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridinecarboxamide
Nevirapine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: 94 percent / 4 h / 140 °C 2: 67 percent / 80percent NaH / bis-(2-methoxy-ethyl) ether / 1.5 h / 185 °C View Scheme | |
Multi-step reaction with 2 steps 1: 83 percent / xylene / 18 h / 110 °C 2: 67 percent / NaH / various solvent(s) / 1.5 h / Heating View Scheme | |
Multi-step reaction with 2 steps 1: calcium oxide / xylene / 140 °C 2: sodium hydrogen sulfate; copper(l) iodide; sulfuric acid; potassium tert-butylate / diethylene glycol dimethyl ether / 115 °C View Scheme |
Molecular structure of Nevirapine (CAS NO.129618-40-2) is:
Product Name: Nevirapine
CAS Registry Number: 129618-40-2
Molecular Weight: 266.29786 [g/mol]
Molecular Formula: C15H14N4O
XLogP3-AA: 2
H-Bond Donor: 1
H-Bond Acceptor: 4
Melting Point: 247 °C
Surface Tension: 66.3 dyne/cm
Density: 1.351 g/cm3
Flash Point: 205 °C
Enthalpy of Vaporization: 66.85 kJ/mol
Boiling Point: 415.4 °C at 760 mmHg
Vapour Pressure: 4.13E-07 mmHg at 25°C
Product Categories: Active Pharmaceutical Ingredients;API;Anti-virals;Inhibitors;Intermediates & Fine Chemicals;Non-nucleoside Reverse Transcriptase;Pharmaceuticals
Nevirapine (CAS NO.129618-40-2) was discovered by Hargrave et al. at Boehringer Ingelheim Pharmaceuticals, Inc., one of the Boehringer Ingelheim group of companies. It is covered by U.S. Patent 5,366,972 and corresponding foreign patents. It was the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was approved June 21, 1996 for adults and September 11, 1998 for children. It was also approved in Europe in 1997.
Nevirapine (CAS NO.129618-40-2) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD | oral | > 3200mg/kg (3200mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 2209, 1999. | |
rat | LDLo | oral | 400mg/kg (400mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 2209, 1999. |
Hazard Codes: Xi
Risk Statements: 36/37/38
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36-37/39
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36:Wear suitable protective clothing.
S37/39:Wear suitable gloves and eye/face protection.
Nevirapine , its cas register number is 129618-40-2. It also can be called Viramune ; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one ; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- .It is a crystalline solid. It has also been tested in trials in Africa, some of which have been highly controversial.